loading
Brainstorm Cell Therapeutics Inc stock is traded at $1.1917, with a volume of 80,931. It is down -1.51% in the last 24 hours and down -47.04% over the past month. Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$1.21
Open:
$1.23
24h Volume:
80,931
Relative Volume:
1.17
Market Cap:
$6.43M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-2.0198
EPS:
-0.59
Net Cash Flow:
$-21.84M
1W Performance:
-2.32%
1M Performance:
-47.04%
6M Performance:
-84.72%
1Y Performance:
-55.86%
1-Day Range:
Value
$1.19
$1.30
1-Week Range:
Value
$1.05
$1.30
52-Week Range:
Value
$1.05
$11.89

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Name
Name
Brainstorm Cell Therapeutics Inc
Name
Phone
201-488-0460
Name
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Name
Employee
29
Name
Twitter
@BrainStormCell
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BCLI's Discussions on Twitter

Compare BCLI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BCLI 1.19 6.43M 0 -16.63M -21.84M -0.59
VRTX 467.64 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.02 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.78 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.25 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.63 24.08B 3.30B -501.07M 1.03B 11.54

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-04-21 Upgrade Maxim Group Hold → Buy
Nov-17-20 Downgrade Maxim Group Buy → Hold
Dec-19-16 Reiterated Maxim Group Buy
Dec-22-15 Reiterated Maxim Group Buy

Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News

pulisher
01:55 AM

Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR

01:55 AM
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve

Nov 14, 2024
pulisher
Nov 11, 2024

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire

Nov 11, 2024
pulisher
Nov 11, 2024

BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | BCLI Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Amyotrophic Lateral Sclerosis Market Opportunities, - openPR

Nov 11, 2024
pulisher
Nov 08, 2024

Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Oct 30, 2024

BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India

Oct 30, 2024
pulisher
Oct 30, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire

Oct 30, 2024
pulisher
Oct 29, 2024

Neuromuscular Disease Therapeutics Market Statistical - openPR

Oct 29, 2024
pulisher
Oct 28, 2024

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PR Newswire

Oct 28, 2024
pulisher
Oct 27, 2024

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat

Oct 27, 2024
pulisher
Oct 18, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR

Oct 17, 2024
pulisher
Oct 16, 2024

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne

Oct 16, 2024
pulisher
Oct 11, 2024

Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트

Oct 11, 2024
pulisher
Oct 10, 2024

Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv

Oct 10, 2024
pulisher
Oct 09, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 07, 2024
pulisher
Oct 07, 2024

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

Gene and Cell Therapies for CNS Disorders Market to Experience - openPR

Oct 04, 2024
pulisher
Oct 02, 2024

Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada

Oct 02, 2024
pulisher
Oct 02, 2024

Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks

Oct 01, 2024
pulisher
Oct 01, 2024

Brainstorm Cell Therapeutics, Inc. (BCLI) requires closer examination - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io

Oct 01, 2024
pulisher
Oct 01, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com - Defense World

Oct 01, 2024
pulisher
Sep 30, 2024

Market Momentum: Brainstorm Cell Therapeutics, Inc. (BCLI) Registers a -12.57 Decrease, Closing at 0.22 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Brainstorm Cell Therapeutics, Inc. (BCLI) Stock: A Year of Market Fluctuations - The InvestChronicle

Sep 30, 2024
pulisher
Sep 30, 2024

The Potential Rise in the Price of Brainstorm Cell Therapeutics, Inc. (BCLI) following insiders activity - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

Cell Therapy Technologies Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 - WhaTech

Sep 30, 2024
pulisher
Sep 28, 2024

Brainstorm Cell Therapeutics Stock Scheduled to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI) - Defense World

Sep 28, 2024
pulisher
Sep 27, 2024

Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv

Sep 27, 2024
pulisher
Sep 26, 2024

BrainStorm announces reverse stock split - Investing.com

Sep 26, 2024
pulisher
Sep 25, 2024

Stem Cell Therapy Market Growth, Size, Research Report and Forecast (2024-2034) - 대구포스트

Sep 25, 2024
pulisher
Sep 24, 2024

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - PR Newswire

Sep 24, 2024
pulisher
Sep 24, 2024

Global Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR GrowthGlobal Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR Growth - 대구포스트

Sep 24, 2024
pulisher
Sep 23, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World

Sep 23, 2024
pulisher
Sep 20, 2024

Cell Theraputics Market 2024-2032 Analysis - Economica

Sep 20, 2024
pulisher
Sep 19, 2024

Balance Sheet Insights: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Sep 19, 2024
pulisher
Sep 19, 2024

BCLI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Sep 19, 2024
pulisher
Sep 17, 2024

SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

Sep 17, 2024
pulisher
Sep 16, 2024

Brainstorm Cell Therapeutics expands stock incentive plans - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Brainstorm Cell Therapeutics expands stock incentive plans By Investing.com - Investing.com Canada

Sep 16, 2024
pulisher
Sep 16, 2024

Brainstorm Cell Therapeutics Enacts Key Corporate Changes - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 16, 2024
pulisher
Sep 13, 2024

Global Stem Cell Therapy Market Technology, Dimension, Vertical, and Regional Insights 2024-2032 - 대구포스트

Sep 13, 2024

Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lebovits Chaim
President & CEO
Sep 30 '24
Buy
0.23
22,000
5,016
1,186,865
Dagher Ibrahim B.
Chief Medical Officer
Jul 19 '24
Sale
0.35
63,000
22,069
0
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):